Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
myeloid leukemia | — | D007951 | C92 |
Expiration | Code | ||
---|---|---|---|
PONATINIB HYDROCHLORIDE, ICLUSIG, TAKEDA PHARMS USA | |||
2023-12-18 | I-849 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Ponatinib Hydrochloride, Iclusig, Takeda Pharms Usa | |||
9493470 | 2033-12-12 | DS, DP | U-1700, U-1948 |
11192895 | 2033-12-12 | U-1700, U-1701, U-1948 | |
11192897 | 2033-12-12 | DP | U-1700, U-1701, U-1948 |
11384086 | 2033-12-12 | DS, DP | U-1700, U-1701, U-1948 |
8114874 | 2027-01-24 | DS, DP | |
9029533 | 2026-12-22 | U-836, U-1283, U-1699, U-1700, U-1701 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 16 | 1 | — | 4 | 23 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 5 | 11 | 1 | — | 7 | 21 |
Myeloid leukemia chronic-phase | D015466 | — | — | 2 | 9 | 1 | — | 1 | 12 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 5 | 1 | — | — | 5 |
Residual neoplasm | D018365 | — | — | — | 2 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 7 | — | — | 1 | 10 |
Leukemia | D007938 | — | C95 | 2 | 4 | — | — | 2 | 6 |
Philadelphia chromosome | D010677 | — | — | 1 | 4 | — | — | 1 | 5 |
Neoplasms | D009369 | — | C80 | 1 | 3 | — | — | — | 3 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 1 | — | — | — | 2 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 2 | — | — | — | 2 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | 1 | — | — | — | 1 |
Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
Myeloid leukemia | D007951 | — | C92 | — | — | — | — | 1 | 1 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | — | — | — | — | 1 | 1 |
Drug common name | Ponatinib |
INN | ponatinib |
Description | Ponatinib is a benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a N-methylpiperazine, a member of benzamides, an acetylenic compound, an imidazopyridazine and a member of (trifluoromethyl)benzenes. It is a conjugate base of a ponatinib(1+). |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12 |
PDB | — |
CAS-ID | 943319-70-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1171837 |
ChEBI ID | 78543 |
PubChem CID | 24826799 |
DrugBank | DB08901 |
UNII ID | 4340891KFS (ChemIDplus, GSRS) |